LEUPROLIDE ACETATE
LHRH(GNRH) AGONIST ANALOG PITUITARY SUPPRESSANTS · ADVANCED PROSTATIC CARCINOMA ·+1
ZYDUS PHARMACEU
Drug class
LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer
The phrase "LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer" represents a descriptive formulary or compendial grouping rather than a single standardized pharmacological class, encompassing both gonadotropin-releasing hormone agonists and antagonists indicated for androgen deprivation therapy. Read more about LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer
28 drugs in this class 15 manufacturers
Drugs in LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer
Filter & compare in the drug finder →
Opens the drug finder with LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer preselected. Add indication or manufacturer filters there.
The phrase "LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer" represents a descriptive formulary or compendial grouping rather than a single standardized pharmacological class, encompassing both gonadotropin-releasing hormone agonists and antagonists indicated for androgen deprivation therapy.
These agents modulate pituitary gonadotropin-releasing hormone receptors: agonists induce receptor downregulation following an initial surge, whereas antagonists directly and competitively block the receptors without an initial surge.
Both mechanisms ultimately suppress luteinizing hormone and follicle-stimulating hormone secretion, reducing serum testosterone to castrate levels to inhibit androgen-dependent tumor growth.
Clinically, these medications are primarily indicated for the management of advanced, metastatic, or locally advanced prostate cancer.
-
nih.gov
The phrase "LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer" represents a descriptive formulary or compendial grouping rather than a single standardized pharmacological class, encompassing both gonadotropin-releasing hormone agonists and antagonists indicated for androgen deprivation therapy These agents modulate pituitary gonadotropin-releasing hormone receptors: agonists induce receptor downregulation following an initial surge, whereas antagonists directly and competitively block the ...
-
urologytimes.com
The phrase "LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer" represents a descriptive formulary or compendial grouping rather than a single standardized pharmacological class, encompassing both gonadotropin-releasing hormone agonists and antagonists indicated for androgen deprivation therapy Both mechanisms ultimately suppress luteinizing hormone and follicle-stimulating hormone secretion, reducing serum testosterone to castrate levels to inhibit androgen-dependent tumor growth
-
researchgate.net
The phrase "LHrH(GNrH) Antagonist/Agonist to Treat Prostatic Cancer" represents a descriptive formulary or compendial grouping rather than a single standardized pharmacological class, encompassing both gonadotropin-releasing hormone agonists and antagonists indicated for androgen deprivation therapy Clinically, these medications are primarily indicated for the management of advanced, metastatic, or locally advanced prostate cancer
-
cancernetwork.com
These agents modulate pituitary gonadotropin-releasing hormone receptors: agonists induce receptor downregulation following an initial surge, whereas antagonists directly and competitively block the receptors without an initial surge Clinically, these medications are primarily indicated for the management of advanced, metastatic, or locally advanced prostate cancer
-
treatmentgps.com
Clinically, these medications are primarily indicated for the management of advanced, metastatic, or locally advanced prostate cancer
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.